Obesity And Covid-19: A Descriptive Review by Ferro, Cibele Alexandra et al.































































Page 73 of 79 
 
Obesity And Covid-19: A Descriptive Review 
Cibele Alexandra Ferro 1, Manuela Guedes Pereira 1, Maria Júlia Busnardo Aguena 1, Vítor 
Afonso Favaretto 1, Idiberto José Zotarelli-Filho 2,3,4, Ana Valéria Garcia Ramirez 2,5, Durval 
Ribas Filho 1,2 
1 FAMECA, Faculty of Medicine of Catanduva - Padre Albino University Center, Catanduva/SP, Brazil. 
2 Associação Brasileira de Nutrologia (ABRAN)/Brazilian Association of Nutrology, Catanduva/SP, Brazil. 
3 FACERES – Faculty of medicine of São José do Rio Preto/SP, Brazil. 
4 Zotarelli-Filho Scientific Work, São José do Rio Preto/SP, Brazil. 
5 Ana Valeria Ramirez Clínica- Clinic of Nutrition and Health Science, São José do Rio Preto SP, Brazil. 
*Corresponding author Email: dr.idibertozotarelli@faceres.com.br 
 DOI: https://doi.org/10.34256/mdnt21113         
Received: 26-01-2021; Accepted: 29-1-2021; Published: 02-2-2021 
Abstract: Introduction: According to data provided by the World Health Organization (WHO), 5,941,223 
confirmed cases and 366,601 deaths had already been reported by May 31, 2020. Higher rates of infection, 
hospitalization, submission to the Intensive Care Units, and fatalities were attributed to obese patients. Objective: 
To gather the available data on obesity and SARS-CoV-2 infection. The study specifically covers combined 
pathophysiology and prognosis and will be updated until September 2020. Methods: This is a literature review 
study with a narrative-descriptive approach. The search was carried out in September 2020, with the totality of 
articles from that same year, when the pandemic of the new coronavirus was declared by the World Health 
Organization. Results: The search on the data platform resulted in 121 articles, of which 86 were classified as 
reviews and 35, systematic reviews, totaling 18 reviews and 7 systematic reviews at the end, with a total value of 
16 articles with sufficient quality. Obesity is associated with increased severity of COVID-19 in the infected 
individual with this disease, due to the chronic inflammatory process, with high levels of pro-inflammatory leptin 
and a lower concentration of anti-inflammatory adiponectin, which causes a response delayed and inferior immune 
system. Conclusion: Individuals with this association have an easier time in the formation of possible clots, due to 
chronic inflammation and impaired fibrinolysis, which qualifies them as individuals of significant thrombogenic risk. 
Thus, individuals with obesity are an important risk group when considering its association with the disease of the 
new coronavirus. 
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1. Introduction 
 The year 2020 was undoubtedly marked by 
something that before was believed to be possible to 
contemplate only on movie screens or in history books: 
a pandemic. The protagonist - who would later be 
designated as COVID-19 (Coronavirus Disease–) was 
first noticed in Wuhan, capital of Hubei province, 
China. As an etiological agent, the SARS-CoV-2 virus 
(Severe Acute) was identified. Respiratory Syndrome 
Coronavirus 2), from a well-known family - that of the 
coronaviruses - that has the SARS-CoV and MERS-CoV 
(Middle East Respiratory Syndrome) viruses as 
representatives, both were responsible for previous 
epidemics, in the years 2003 and 2012, respectively. 
The first cases of the disease, recorded 
between December 2019 and January 2020, were 
quickly followed by thousands of others around the 
globe. According to data provided by the World Health 
Organization (WHO), 5,941,223 confirmed cases and 
366,601 deaths had already been reported by May 31, 
2020 [1]. In August, ten were the countries that had 
not yet registered cases of the disease [2]. By the end 
of September, the number of deaths had already 
surpassed the first million, and the number of cases, 
33 million [3]. 
Given this scenario, it is not difficult to 
understand why the billions of inhabitants of the entire 
planet had to be quarantined and to adapt to the “new 
normal” configured by this reality. For the first time in 
the contemporary world, there has been an 
extraordinarily rapid spread of a virus, which causes a 
disease with a broad spectrum of clinical presentation 
and severity of symptoms. SARS-CoV-2 infection is 
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known coronaviruses. In the classic form, the initial flu 
symptoms (fever, dry cough) can quickly progress to 
interstitial pneumonia and acute respiratory distress 
syndrome (ARDS) [4]. It is common for patients to 
evolve with loss of olfactory and gustatory sensitivities, 
in addition to presenting gastrointestinal symptoms 
and, eventually, a series of microvascular and 
inflammatory complications. It is worth mentioning 
that many of the patients are infected silently and 
remain asymptomatic. Also, many studies are still 
needed to address other possible findings, which 
remain unclear. 
Among these findings, the one mentioned 
below is perhaps the most emblematic. The 
exacerbated increase in a series of inflammation 
markers, what became known as a “cytokine storm”, 
and the consequent imbalance between anti- and pro-
inflammatory factors lead to an important breakdown 
of homeostasis, which is closely associated with a 
worse prognosis of disease. After countless 
observations and tests carried out in this regard, 
evidence was found that some situations were related 
to a more severe form of presentation of this “storm”, 
such as arterial hypertension, diabetes mellitus and 
cardiovascular diseases [5]. Interestingly - or not - the 
fact is that the disorders presented have one factor in 
common: in most cases in which they manifest 
themselves, they are linked to obesity, a condition that 
has proven to be one of the greatest risk factors for 
COVID-19. 
Many of the patients hospitalized by COVID-19 
have a Body Mass Index (BMI) corresponding to grade 
I obesity [6]. These patients have a higher chance of 
complications and need for invasive mechanical 
ventilation, and most of them have diabetes, which, as 
already mentioned, is one of the most common 
comorbidities of obesity. On the other hand, the 
relationship between high body mass indexes and the 
development of various types of cancer has long been 
researched and investigated [7]. Thus, it is clear that 
excess body weight, especially visceral fat, is linked to 
the appearance and/or worsening of these and other 
conditions [8] throughout the evolution of its 
pathophysiology - a term that is properly applied since 
obesity is considered and behaves like a disease. 
Therefore, it is possible to conclude that it can be 
considered a potential threat in its own right, being as 
or more relevant than its comorbidities. 
The finding of obesity as a risk factor in 
COVID-19 by the CDC (Centers for Disease Control and 
Prevention), an agency of the United States 
Department of Health and Human Services, was not at 
all surprising. This factor had already been shown to 
be relevant in the course of other infectious diseases, 
including respiratory diseases. So, it was with influenza 
A, caused by the H1N1 virus and the cause of an 
epidemic in 2009 [9]. In this context, higher rates of 
infection, hospitalization, submission to the Intensive 
Care Units (ICU), and fatalities were attributed to 
obese patients. 
The explanation for this correlation is due to 
several factors, which will be further explored in the 
course of this review. First of all are the mechanical 
obstacles represented by the deposition of body fat, 
impairing the performance of the respiratory muscles 
and lungs. On the other hand, there is a series of 
molecular mechanisms involved in the chronic 
inflammatory state induced by obesity, which triggers 
endothelial dysfunction and coagulative disorders. The 
endocrine-metabolic and immune systems are no less 
affected by the condition. This evidence exemplifies 
only some of the ways in which obesity is an entity 
that must be seriously considered in the midst of the 
COVID-19 pandemic. 
When analyzing the profile of the world 
population in terms of indicators such as BMI, we are 
faced with a worrying context, mainly from the point of 
view of public health and its demand. According to a 
report released by the WHO in December 2019, about 
2.3 billion children and adults worldwide are 
overweight or obese [10]. The distribution of this 
number is significant not only in high-income countries 
but also in those of low and middle income, where it 
contrasts with high levels of malnutrition [11]. In 
Brazil, the situation is no different. This chronic disease 
increased 67.8% in twelve years, from 11.8% in 2006 
to 19.8% in 2018. In 2018, 20.7% of women and 
18.7% of men were obese [12]. 
Given the current epidemiological scenario in 
Brazil and in the world, obesity presents itself as a very 
interesting and necessary study object, as are the 
identification, prevention, and intervention strategies 
to be carried out in the population. Providing support 
to these patients, from primary to quaternary 
prevention, is the biggest challenge facing the Unified 
Health System (SUS) and other systems around the 
globe. And, in the current pandemic context of COVID-
19, it is to be expected that this challenge will be even 
greater, as well as the relevance of studies that value 
for historically and technically correlating these two 
pandemics - COVID-19 and obesity -, coming in line 
with the purpose of this review. 
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This review aimed to gather the available data 
on obesity and SARS-CoV-2 infection. The study 
specifically covers combined pathophysiology and 
prognosis and will be updated until September 2020. 
 
2. Methods 
This is a literature review study with a 
narrative-descriptive approach. The database for 
research was PubMed®, in which the descriptors of 
obesity and COVID-19 were used to search for articles. 
Among the descriptors COVID-19, SARS-CoV-2, 
Obesity, Inflammatory processes, and Cytokines, the 
booleans “and”, “or” or “not” were used. The time 
frame was 5 years. The search was carried out in 
September 2020, with the totality of articles from that 
same year, when the pandemic of the new coronavirus 
was declared by the World Health Organization. 
Only systematic reviews and reviews that 
covered the selected subject descriptors and were 
written in English were selected. After the research, 
the articles were screened by the classification of 
CAPES journals, so that only articles whose journals 
were classified as A or B qualifications according to 
CAPES were used to prepare this review. C-rated or 
unrated articles were excluded. Finally, the articles 
were read to verify their agreement with the theme 



















The search on the data platform resulted in 
121 articles, of which 86 were classified as reviews and 
35, systematic reviews (Figure 1). From reading the 
articles to assess the link between obesity and SARS-
Cov-2 infection, articles in which there was a causal 
link between the descriptors used were excluded, 
totaling 18 reviews and 7 systematic reviews at the 
end (Table 1), with a total value of 16 articles with 
sufficient quality and used in full (Table 2). 
 
4. Discussion 
Obesity, defined by a body mass index (BMI) 
above 30 kg/m², is characterized by the expansion and 
inflammation of visceral adipose tissue, which secretes 
pro-inflammatory cytokines, adipokines, and molecules 
with broad pathophysiological effects [11]. 
Paradoxically, obesity is not synonymous with an 
excess nutritional status. On the contrary, most obese 
people are in deficient states of vitamins and nutrients 
- which contributes to an even worse picture of 
COVID-19 [12]. The exacerbated consumption of 
saturated fats, sugars, and refined carbohydrates 
favors the prevalence of overweight and also type 2 
diabetes, frequent comorbidity, and, likewise, 
identified as a risk factor for COVID-19 [13, 14]. 
 
 
Figure 1 Results obtained from the adopted methodological sequence. 
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Both clinical entities are characterized by a 
chronic inflammatory process, with higher values of 
leptin (pro-inflammatory molecule) and a lower 
concentration of anti-inflammatory adiponectin, 
causing a delayed and lower immune response, with a 
decrease in macrophages in the course of infection 
[14, 15]. 
The excessive inflammation found in obese 
individuals with COVID-19 is a result of metabolic 
tissue stress induced by weight gain and unilocular 
adipose tissue dysfunction. This tissue is an important 
energy reservoir, formed by adipocytes (continent of 
lipids), immunity endothelial cells, and other 
components [16]. In obesity, adipocytes undergo 
hyperplasia and hypertrophy, which results in a large 
expression of pro-inflammatory cytokines, causing 
hypoxia toxicity of the microenvironment, with tissue 
necrosis and activation of the immune system 
response.  
B, T lymphocytes and NK cells (natural killers), 
together with macrophages, secrete high rates of IL-6 
and TNF-𝛼, which lead to the establishment of chronic 
inflammation. This affects the metabolism, leading to 
the appearance of comorbidities. In addition, the drop 
in IFN-1 and other molecules that help to regulate the 
desirable performance of the immune system 
constitutes a deficient immune response and greater 
susceptibility to an aggressive viral infection [17]. 
The literature reveals a direct metabolic link 
between the inflammatory state of obesity and the 
“cytokine storm” seen in those infected with the SARS-














This hyperinflammatory state leads to a rapid 
respiratory decline in these patients [18], proving the 
direct implication of excess weight in the prognosis of 
the disease. The performance of physical activity, with 
moderate frequency and intensity, controls adiposity, 
the inflammatory profile, the immune response, and 
the endocrine activity of the individual, which results in 
a decrease in the inflammatory process of adipose 
tissue [19]. 
The current clinical experience reported in the 
studies has shown that about 40% of patients with 
COVID-19 hospitalized in intensive care units are 
obese and have a higher risk of developing respiratory 
complications, such as ARDS, in addition to greater 
difficulty in intubation, when necessary respiratory 
support [11, 20-22]. This is due to changes in the 
baseline respiratory mechanics resulting from obesity. 
As a consequence, there is a reduction in total lung 
capacity, functional residual capacity, and vital 
capacity, as well as an increase in pleural pressure and 
upper airway resistance, with the potential to induce or 
worsen asthma, dyspnea, and wheezing [16, 23]. In 
addition, obese patients may suffer from rapid 
oxyhemoglobin desaturation when previously 
hypoxemic [23] and represent a greater risk of 
extubation failure, in view of upper airway obstruction, 
aggravated by changes in rostral fluid and sedatives, 
with underlying hypoxemia [23]. Ventilation through 
the bag-valve-mask is also challenging for the 
attendant when dealing with an obese patient [23]. 
Returning to molecular events, it is known that 
the entry of the SARS-CoV-2 virus into cells is 
mediated by the receptor for the angiotensin-
Table 1 Number of articles obtained and classification according to the 
type of study 
 Reviews Systematic Reviews Total 
Articles Found 86 35 121 
Selected Articles 18 7 25 
Table 2 Articles found and used according to the  
classification of CAPES journals 
 Articles Found Articles Used 
Qualis A 42 11 
Qualis B 45 14 
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converting enzyme 2 (ACE-2). In turn, hypertrophy of 
fat cells promotes increased expression of this receptor 
[24], which facilitates infection and makes adipose 
tissue an important viral reservoir. The infection also 
blocks the pathway of beneficial vasodilatory effects of 
angiotensin II [19] and intensifies its vasoconstrictor, 
pro-inflammatory, and pro-oxidant activity. This 
increases the risk of acute lung injury [3], making the 
lungs and the heart vulnerable to the virus [25-27]. 
As for the endocrine effects, there is leptin. It 
is a peptide hormone produced by adipocytes, whose 
main function is to regulate satiety, but it is also an 
important mediator of pulmonary immunity. Some 
studies have shown that hunger and leptin deficiency 
are associated with decreased immune reactivity, in 
the same way, that hyperleptinemia has also been 
shown to have detrimental effects on the immune 
response. Elevated serum leptin levels, as in obesity, 
are linked to a reduction in the main inflammatory 
biomarkers and to an attenuated response to ARDS 
and pneumonia, worsening the results of these 
conditions [28]. 
Another aspect of the COVID-19 relationship 
and obesity addressed in the articles involves furin, a 
protease found in the basal endothelial membrane. It 
allows the conversion of some latent precursor 
proteins to their active form, being used even for 
certain pathogens to become functional. Some of these 
pathogens constitute bacterial toxins and certain viral 
envelopes, as in the case of HIV and Ebola viruses, in 
addition to the spike proteins of SARS-Cov-2. When 
activated by furin, the SARS-Cov-2 virus causes 
endothelial dysfunction, diffuse inflammation of the 
vascular tissue, and micro and macrovascular 
thrombosis in the arterial and venous circulations. And, 
interestingly, protease was found to be abundant 
especially in mononuclear inflammatory cells, playing a 
signaling role towards adipocytes. This signaling, in the 
long term, leads to blood vessel remodeling and 
atherosclerosis, due to lipid deposition. Entities such as 
diabetes, hypercholesterolemia, and obesity are 
associated with increased levels of furin, which 
constitutes another aggravating factor for the 
complications associated with COVID-19 [29]. 
Thus, the focus on furin host cells can bring 
potential therapeutic options against infections whose 
agents depend on this protease to become functional 
and develop high pathogenicity [29]. Obesity also 
represents a risk factor for thrombotic disorders, such 
as deep vein thrombosis and pulmonary embolism, due 
to chronic inflammation and impaired fibrinolysis [30]. 
In these cases, laboratory markers point to an increase 
in coagulation factors, such as D-dimer and fibrinogen 
[31]. In patients hospitalized with COVID-19, the 
World Health Organization recommends the 
prescription of low molecular weight heparin or 
unfractionated heparin in prophylactic doses to prevent 
venous thromboembolism [14, 29]. 
 
5. Conclusion 
Obesity is associated with increased severity of 
COVID-19 in the infected individual with this disease, 
due to the chronic inflammatory process, with high 
levels of pro-inflammatory leptin and a lower 
concentration of anti-inflammatory adiponectin, which 
causes a response delayed and inferior immune 
system. Also, the obese patient has drop-in cytokines 
that help in the immune response to viral infection, 
which leads to a worse prognosis in these patients 
when affected by COVID-19. Furthermore, individuals 
with this association have an easier time in the 
formation of possible clots, due to chronic 
inflammation and impaired fibrinolysis, which qualifies 
them as individuals of significant thrombogenic risk. 
Therefore, within the reviewed articles and after 
collecting available data, it is concluded that individuals 
with obesity are an important risk group when 
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